EP1550720A4
Mutated androgen receptor, cancer cells expressing the same, method of constructing the same and use thereof
Abstract
This record has no abstract on file.
Term
Term ended
Projected expiry passed 2 June 2023, 3.3 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
13 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13
Every citation, both ways
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| EP1466902A1 | Cites | European Patent Office (EPO) | E | Search report | 5-11,17,42-49,56-58 |
| EP1466902A | Cites | European Patent Office (EPO) | – | – | – |
| ZHAO ET AL: "TWO MUTATIONS IDENTIFIED IN THE ANDROGEN RECEPTOR OF THE NEW HUMAN PROSTATE CANCER CELL LINE MDA PCA 2A", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 162, no. 11, December 1999 (1999-12-01), pages 2192 - 2199, XP005376218, ISSN: 0022-5347 | Non-patent | – | – | Search report | – |
| BENTEL J M ET AL: "ANDROGEN RECEPTOR EXPRESSION IN PRIMARY PROSTATE CANCERS OF LOBUND-WISTAR RATS AND IN TUMOR-DERIVED CELL LINES", IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY. ANIMAL, TISSUE CULTURE ASSOCIATION, COLUMBIA, MD, US, vol. 35, no. 10, November 1999 (1999-11-01), pages 655 - 662, XP009026700, ISSN: 1071-2690 | Non-patent | – | – | Search report | – |
| KOKONTIS J M ET AL: "PROGRESSION OF LNCAP PROSTATE TUMOR GELLS DURING ANDROGEN DEPRIVATION: HORMONE-INDEPENDENT GROWTH, REPRESSION OF PROLIFERATION BY ANDROGEN, AND ROLE FOR P27KIP1 IN ANDROGEN-INDUCED CELL CYCLE ARREST", MOLECULAR ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 12, 1998, pages 941 - 953, XP002916571, ISSN: 0888-8809 | Non-patent | – | – | Search report | – |
| VELDSCHOLTE J ET AL: "A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 173, no. 2, 14 December 1990 (1990-12-14), pages 534 - 540, XP002972371, ISSN: 0006-291X | Non-patent | – | – | Search report | – |
| HARA TAKAHITO ET AL: "Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.", CANCER RESEARCH. 1 JAN 2003, vol. 63, no. 1, 1 January 2003 (2003-01-01), pages 149 - 153, XP002382326, ISSN: 0008-5472 | Non-patent | – | – | Search report | – |
| HAAPALA K ET AL: "Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide.", LABORATORY INVESTIGATION; A JOURNAL OF TECHNICAL METHODS AND PATHOLOGY. DEC 2001, vol. 81, no. 12, December 2001 (2001-12-01), pages 1647 - 1651, XP002382327, ISSN: 0023-6837 | Non-patent | – | – | Search report | – |
| GOTTLIEB BRUCE ET AL: "Update of the androgen receptor gene mutations database", HUMAN MUTATION, WILEY-LISS, NEW YORK, NY, US, vol. 14, no. 2, 1999, pages 103 - 114, XP002173777, ISSN: 1059-7794 | Non-patent | – | – | Search report | – |
| See also references of WO 03102188A1 | Non-patent | – | – | Search report | – |
14 members in 7 offices; this record represents the family
Priority claims5
| Document | Office | Kind | Date |
|---|---|---|---|
| 2002162206 | Japan | – | |
| 2002162206 | Japan | A | |
| 2002255612 | Japan | – | |
| 2002255612 | Japan | A | |
| 0306942 | Japan | W |
Members14
| Document | Office | Kind | |
|---|---|---|---|
| WO03102188A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU2003241738A1 | Australia | A1 | |
| JP2004057180A | Japan | A | |
| EP1550720A1 | European Patent Office (EPO) | A1 | |
| US2005181462A1 | United States of America | A1 | |
| EP1550720A4This record | European Patent Office (EPO) | A4 | |
| JP2009005703A | Japan | A | |
| EP2090656A1 | European Patent Office (EPO) | A1 | |
| JP4378415B2 | Japan | B2 | |
| EP1550720B1 | European Patent Office (EPO) | B1 | |
| JP4447826B2 | Japan | B2 | |
| AT462724T | Austria | T | |
| ATE462724T1 | Austria | T1 | |
| DE60331934D1 | Germany | D1 |
60 legal events, as 7 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Notification of lapseLapsedST | ST | FR | |
| Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal feeWithdrawnR119 | R119 | DE | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal feeWithdrawnR119 | R119 | DE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Change of the address of the representativeNEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH)PCAR | PCAR | CH | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Discontinued in the netherlands as no translation has been filedVDEP | VDEP | NL | |
| Corresponds to:REF | REF | EP | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| New agentNV | NV | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Supplementary search report drawn up and despatchedA4 | A4 | EP | |
| Party data changed (applicant data changed or rights of an application transferred)RAP1 | RAP1 | EP | |
| Request for extension of the european patent (deleted)DAX | DAX | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1550720
- Application
- 37307782
Titles3
- German
- MUTIERTER ANDROGENREZEPTOR, DIESEN EXPRIMIERENDE KREBSZELLEN, VERFAHREN ZUR KONSTRUKTION DAVON UND VERWENDUNG DAVON
- English
- MUTATED ANDROGEN RECEPTOR, CANCER CELLS EXPRESSING THE SAME, METHOD OF CONSTRUCTING THE SAME AND USE THEREOF
- French
- RECEPTEUR D'ANDROGENE MUTE, CELLULES CANCEREUSES L'EXPRIMANT, PROCEDE DE CONSTRUCTION DE CE RECEPTEUR ET UTILISATIONS CORRESPONDANTES
Classification
- CPC, 9
- C07K14/721
- C12N5/0693
- G01N33/5011
- G01N33/74
- A61P35/00
- A61P43/00
- A61P5/28
- G01N33/575
- G01N33/57555
- IPC, 27
- C12N15 12
- C07K14 72
- C07K16 28
- C12N5 10
- C12P21 02
- C12P21 08
- C12Q1 02
- A61K38 17
- A61K39 395
- A61K48 00
- A61P35 00
- G01N33 15
- G01N33 50
- G01N33 53
- G01N33 566
- A61K45 00
- A61P5 28
- A61P43 00
- C12N1 15
- C12N1 19
- C12N1 21
- C12N5 09
- C12N15 09
- C12Q1 68
- C12R1 91
- G01N33 574
- G01N33 74
Designated states27
- Contracting states, 27
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czechia
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Hungary
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Portugal
- Romania
- Sweden
and 3 moreShow fewer
- Slovenia
- Slovakia
- Türkiye